1.A Nationwide Study on HER2-Low Breast Cancer in South Korea: Its Incidence of 2022 Real World Data and the Importance of Immunohistochemical Staining Protocols
Min Chong KIM ; Eun Yoon CHO ; So Yeon PARK ; Hee Jin LEE ; Ji Shin LEE ; Jee Yeon KIM ; Ho-chang LEE ; Jin Ye YOO ; Hee Sung KIM ; Bomi KIM ; Wan Seop KIM ; Nari SHIN ; Young Hee MAENG ; Hun Soo KIM ; Sun Young KWON ; Chungyeul KIM ; Sun-Young JUN ; Gui Young KWON ; Hye Jeong CHOI ; So Mang LEE ; Ji Eun CHOI ; Ae Ri AN ; Hyun Joo CHOI ; EunKyung KIM ; Ahrong KIM ; Ji-Young KIM ; Jeong Yun SHIM ; Gyungyub GONG ; Young Kyung BAE
Cancer Research and Treatment 2024;56(4):1096-1104
		                        		
		                        			 Purpose:
		                        			Notable effectiveness of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)–low advanced breast cancer (BC) has focused pathologists’ attention. We studied the incidence and clinicopathologic characteristics of HER2-low BC, and the effects of immunohistochemistry (IHC) associated factors on HER2 IHC results. 
		                        		
		                        			Materials and Methods:
		                        			The Breast Pathology Study Group of the Korean Society of Pathologists conducted a nationwide study using real-world data on HER2 status generated between January 2022 and December 2022. Information on HER2 IHC protocols at each participating institution was also collected. 
		                        		
		                        			Results:
		                        			Total 11,416 patients from 25 institutions included in this study. Of these patients, 40.7% (range, 6.0% to 76.3%) were classified as HER2-zero, 41.7% (range, 10.5% to 69.1%) as HER2-low, and 17.5% (range, 6.7% to 34.0%) as HER2-positive. HER2-low tumors were associated with positive estrogen receptor and progesterone receptor statuses (p < 0.001 and p < 0.001, respectively). Antigen retrieval times (≥ 36 minutes vs. < 36 minutes) and antibody incubation times (≥ 12 minutes vs. < 12 minutes) affected on the frequency of HER2 IHC 1+ BC at institutions using the PATHWAY HER2 (4B5) IHC assay and BenchMark XT or Ultra staining instruments. Furthermore, discordant results between core needle biopsy and subsequent resection specimen HER2 statuses were observed in 24.1% (787/3,259) of the patients. 
		                        		
		                        			Conclusion
		                        			The overall incidence of HER2-low BC in South Korea concurs with those reported in previously published studies. Significant inter-institutional differences in HER2 IHC protocols were observed, and it may have impact on HER2-low status. Thus, we recommend standardizing HER2 IHC conditions to ensure precise patient selection for targeted therapy. 
		                        		
		                        		
		                        		
		                        	
2.Crohn's disease and smoldering multiple myeloma: a case report and literature review.
So Young PARK ; Jae Min KIM ; Hyun Joon KANG ; Minje KIM ; Jae Joon HAN ; Chi Hoon MAENG ; Sun Kyung BAEK ; Hwi Joong YOON ; Si Young KIM ; Hyo Jong KIM
Intestinal Research 2017;15(2):249-254
		                        		
		                        			
		                        			Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that presents with abdominal pain, weight loss, and diarrhea. Although the etiology has not been fully elucidated, both environmental and genetic causes are known to be involved. In chronic inflammatory conditions such as IBD, B lymphocytes are chronically stimulated, and they induce monoclonal expansion of plasma cells, sometimes resulting in monoclonal gammopathy of undetermined significance. Immunomodulators that are commonly used to control inflammation, such as tumor necrosis factor-α (TNF-α) blockers could increase the possibility of hematologic malignancy. The pathogenesis of multiple myeloma in association with TNF-α inhibitor therapy is attributed to decreased apoptosis of plasma cell populations. Here, we describe a case of a 36-year-old male patient who was diagnosed with immunoglobulin A subtype smoldering multiple myeloma during the treatment for CD with infliximab and adalimumab. We report this case along with a review of the literature on cases of multiple myeloma that occurred in conjunction with CD.
		                        		
		                        		
		                        		
		                        			Abdominal Pain
		                        			;
		                        		
		                        			Adalimumab
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Apoptosis
		                        			;
		                        		
		                        			B-Lymphocytes
		                        			;
		                        		
		                        			Crohn Disease*
		                        			;
		                        		
		                        			Diarrhea
		                        			;
		                        		
		                        			Hematologic Neoplasms
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunoglobulin A
		                        			;
		                        		
		                        			Immunologic Factors
		                        			;
		                        		
		                        			Inflammation
		                        			;
		                        		
		                        			Inflammatory Bowel Diseases
		                        			;
		                        		
		                        			Infliximab
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Monoclonal Gammopathy of Undetermined Significance
		                        			;
		                        		
		                        			Multiple Myeloma*
		                        			;
		                        		
		                        			Necrosis
		                        			;
		                        		
		                        			Plasma Cells
		                        			;
		                        		
		                        			Tumor Necrosis Factor-alpha
		                        			;
		                        		
		                        			Weight Loss
		                        			
		                        		
		                        	
3.A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology.
Jun Ho YI ; Jung Hun KANG ; In Gyu HWANG ; Hee Kyung AHN ; Hyun Jin BAEK ; Soon Il LEE ; Do Hyoung LIM ; Young Woong WON ; Jun Ho JI ; Hyo Song KIM ; Sun Young RHA ; Sung Yong OH ; Kyung Eun LEE ; Taekyu LIM ; Chi Hoon MAENG ; Moon Jin KIM ; Seung Tae KIM ; Jeeyun LEE ; Joon Oh PARK ; Young Suk PARK ; Ho Yeong LIM ; Won Ki KANG ; Se Hoon PARK
Cancer Research and Treatment 2016;48(2):553-560
		                        		
		                        			
		                        			PURPOSE: While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. MATERIALS AND METHODS: Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. RESULTS: A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). CONCLUSION: While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.
		                        		
		                        		
		                        		
		                        			Adenocarcinoma
		                        			;
		                        		
		                        			Asian Continental Ancestry Group
		                        			;
		                        		
		                        			Carcinoma, Signet Ring Cell
		                        			;
		                        		
		                        			Disease-Free Survival
		                        			;
		                        		
		                        			Drug Therapy*
		                        			;
		                        		
		                        			Ethnic Groups
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Receptor, erbB-2
		                        			;
		                        		
		                        			Retrospective Studies*
		                        			;
		                        		
		                        			Stomach Neoplasms*
		                        			
		                        		
		                        	
4.Long-term Treatment with Oriental Medicinal Herb Artemisia princeps Alters Neuroplasticity in a Rat Model of Ovarian Hormone Deficiency.
Hyun Bum KIM ; Byeong Jae KWON ; Hyun Ji CHO ; Ji Won KIM ; Jeong Woo CHON ; Moon Ho DO ; Sang Yong PARK ; Sun Yeou KIM ; Sung Ho MAENG ; Yoo Kyoung PARK ; Ji Ho PARK
Experimental Neurobiology 2015;24(1):71-83
		                        		
		                        			
		                        			Artemisia princeps (AP) is a flowering perennial used as a traditional medicine and dietary supplement across East Asia. No study has yet assessed its effects on synaptic plasticity in hippocampus and much less in a model of ovarian hormone deficiency. We examined the influence of chronic oral AP ethanol extract treatment in ovariectomized rats on the induction of long-term depression in a representative synapse (CA3-CA1) of the hippocampus. Ovariectomized rats demonstrated lower trabecular mean bone mineral densities than sham, validating the establishment of pathology. Against this background of pathology, AP-treated ovariectomized rats exhibited attenuated long-term depression (LTD) in CA1 relative to water-treated controls as measured by increased field excitatory post-synaptic potentials (fEPSP) activation averages over the post-stimulation period. While pathological significance of long-term depression (LTD) in ovariectomized rats is conflicting, that AP treatment significantly affected its induction offers justification for further study of its influences on plasticity and its related disorders.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Artemisia*
		                        			;
		                        		
		                        			Bone Density
		                        			;
		                        		
		                        			Depression
		                        			;
		                        		
		                        			Dietary Supplements
		                        			;
		                        		
		                        			Ethanol
		                        			;
		                        		
		                        			Far East
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Flowers
		                        			;
		                        		
		                        			Hippocampus
		                        			;
		                        		
		                        			Medicine, East Asian Traditional
		                        			;
		                        		
		                        			Medicine, Traditional
		                        			;
		                        		
		                        			Models, Animal*
		                        			;
		                        		
		                        			Neuronal Plasticity*
		                        			;
		                        		
		                        			Ovariectomy
		                        			;
		                        		
		                        			Pathology
		                        			;
		                        		
		                        			Plants, Medicinal*
		                        			;
		                        		
		                        			Plastics
		                        			;
		                        		
		                        			Rats
		                        			;
		                        		
		                        			Synapses
		                        			
		                        		
		                        	
5.Comparison of End-of-Life Care Intensity between Cancer and Non-cancer Patients: a Single Center Experience.
Jae Min KIM ; Sun Kyung BAEK ; Si Young KIM ; Chi Hoon MAENG ; Jae Joon HAN ; Soyoung PARK ; Jae Hun PARK
Korean Journal of Hospice and Palliative Care 2015;18(4):322-328
		                        		
		                        			
		                        			PURPOSE: The aging of society has rapidly progressed, especially in Korea. Therefore, the necessity of research on end-of-life (EOL) care in elderly patients has increased. However, there are few studies on EOL care intensity for non-cancer patients. This study was designed to compare the EOL care intensity between cancer and non-cancer patients. METHODS: We retrospectively analyzed the EOL care intensity based on medical records of decedents of Kyung Hee University Medical Center, a tertiary referral hospital from December 2014 through March 2015. And we compared EOL care intensity between cancer patients and non-cancer patients using statistical analysis of the frequency of invasive procedures and logistic regression analysis for factors that affect the EOL care intensity. RESULTS: Statistical analysis showed invasive procedures, such as intensive care unit admission, endotracheal intubation followed by mechanical ventilation and emergency dialysis, were performed more frequently in non-cancer patients than cancer patients (29.3% vs. 72.4%, P<0.001). And age (P=0.038) and morbidity of cancer (P<0.001) influenced the invasive procedural decision when analyzed by logistic regression analysis. CONCLUSION: The EOL care was more intensive in non-cancer patients, and age and morbidity of cancer were major factors for the treatment intensity.
		                        		
		                        		
		                        		
		                        			Academic Medical Centers
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Aging
		                        			;
		                        		
		                        			Decision Making
		                        			;
		                        		
		                        			Dialysis
		                        			;
		                        		
		                        			Emergencies
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Critical Care
		                        			;
		                        		
		                        			Intensive Care Units
		                        			;
		                        		
		                        			Intubation, Intratracheal
		                        			;
		                        		
		                        			Korea
		                        			;
		                        		
		                        			Logistic Models
		                        			;
		                        		
		                        			Medical Records
		                        			;
		                        		
		                        			Respiration, Artificial
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Terminal Care
		                        			;
		                        		
		                        			Tertiary Care Centers
		                        			
		                        		
		                        	
6.Diagnostic Value of Clinical T Staging Assessed by Endoscopy and Stomach Protocol Computed Tomography in Gastric Cancer: The Experience of a Low-Volume Institute.
Tae Hyeon KIM ; Jeong Jae KIM ; Seung Hyoung KIM ; Bong Soo KIM ; Hyun Joo SONG ; Soo Young NA ; Sun Jin BOO ; Heung Up KIM ; Young Hee MAENG ; Chang Lim HYUN ; Kwang Sig KIM ; In Ho JEONG
Journal of Gastric Cancer 2012;12(4):223-231
		                        		
		                        			
		                        			PURPOSE: Clinical staging of gastric cancer appears to be important more and more for tailored therapy. This study aimed to verify the accuracy of clinical T staging in a low-volume institute. MATERIALS AND METHODS: We retrospectively reviewed prospectively collected data of gastric cancer patients who underwent resection. A total of 268 patients of gastric cancer were enrolled from March 2004 to June 2012. These demographics, tumor characteristics, and clinical stages were analyzed for identification of diagnostic value of clinical T staging. RESULTS: The predictive values for pT1 of endoscopy and computed tomography were 90.0% and 89.4%, respectively. In detail, the predictive values of endoscopy for pT1a, pT1b, and pT2 or more were 87%, 58.5%, and 90.6%, respectively. The predictive values of computed tomography for pT1a, pT1b, and pT2 or more were 68.8%, 73.9%, and 84.4%, respectively. The factors leading to underestimation of pT2 or more lesions by gastroscopy were the middle third location, the size greater than 2 cm, and younger age. Those for overestimation of pT1 lesion by computed tomography were male, age more than 70 years, elevated type, and size greater than 3 cm. CONCLUSIONS: Diagnostic accuracy of early gastric cancer was 90%, which is comparable to those of high volume center. In patients with early gastric cancer, limited gastrectomy or minimal invasive surgery can be safely introduced at a low volume center also. However, the surgeon of low-volume institute should consider the accuracy of clinical staging before extending the indication of limited treatment.
		                        		
		                        		
		                        		
		                        			Demography
		                        			;
		                        		
		                        			Endoscopy
		                        			;
		                        		
		                        			Gastrectomy
		                        			;
		                        		
		                        			Gastroscopy
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Neoplasm Staging
		                        			;
		                        		
		                        			Prospective Studies
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Stomach
		                        			;
		                        		
		                        			Stomach Neoplasms
		                        			;
		                        		
		                        			Technology, Radiologic
		                        			
		                        		
		                        	
7.Diagnostic Value of Clinical T Staging Assessed by Endoscopy and Stomach Protocol Computed Tomography in Gastric Cancer: The Experience of a Low-Volume Institute.
Tae Hyeon KIM ; Jeong Jae KIM ; Seung Hyoung KIM ; Bong Soo KIM ; Hyun Joo SONG ; Soo Young NA ; Sun Jin BOO ; Heung Up KIM ; Young Hee MAENG ; Chang Lim HYUN ; Kwang Sig KIM ; In Ho JEONG
Journal of Gastric Cancer 2012;12(4):223-231
		                        		
		                        			
		                        			PURPOSE: Clinical staging of gastric cancer appears to be important more and more for tailored therapy. This study aimed to verify the accuracy of clinical T staging in a low-volume institute. MATERIALS AND METHODS: We retrospectively reviewed prospectively collected data of gastric cancer patients who underwent resection. A total of 268 patients of gastric cancer were enrolled from March 2004 to June 2012. These demographics, tumor characteristics, and clinical stages were analyzed for identification of diagnostic value of clinical T staging. RESULTS: The predictive values for pT1 of endoscopy and computed tomography were 90.0% and 89.4%, respectively. In detail, the predictive values of endoscopy for pT1a, pT1b, and pT2 or more were 87%, 58.5%, and 90.6%, respectively. The predictive values of computed tomography for pT1a, pT1b, and pT2 or more were 68.8%, 73.9%, and 84.4%, respectively. The factors leading to underestimation of pT2 or more lesions by gastroscopy were the middle third location, the size greater than 2 cm, and younger age. Those for overestimation of pT1 lesion by computed tomography were male, age more than 70 years, elevated type, and size greater than 3 cm. CONCLUSIONS: Diagnostic accuracy of early gastric cancer was 90%, which is comparable to those of high volume center. In patients with early gastric cancer, limited gastrectomy or minimal invasive surgery can be safely introduced at a low volume center also. However, the surgeon of low-volume institute should consider the accuracy of clinical staging before extending the indication of limited treatment.
		                        		
		                        		
		                        		
		                        			Demography
		                        			;
		                        		
		                        			Endoscopy
		                        			;
		                        		
		                        			Gastrectomy
		                        			;
		                        		
		                        			Gastroscopy
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Neoplasm Staging
		                        			;
		                        		
		                        			Prospective Studies
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Stomach
		                        			;
		                        		
		                        			Stomach Neoplasms
		                        			;
		                        		
		                        			Technology, Radiologic
		                        			
		                        		
		                        	
8.Cystic Adventitial Disease of the Popliteal Artery: Resection and Repair with Autologous Vein Patch.
Young Hee MAENG ; Jee Won CHANG ; Sun Hyung KIM
The Korean Journal of Thoracic and Cardiovascular Surgery 2011;44(3):266-268
		                        		
		                        			
		                        			Cystic adventitial disease is rare, but it is one of the well-recognized causes of non-atherosclerotic arterial stenosis or obstruction. Despite one of its most common symptoms being chronic intermittent claudication, it may be misdiagnosed as arterial embolism when presented with acute ischemic symptoms. Surgical resection is recommended because of recurrence or a low success rate with aspiration or endovascular stent. We performed resection and repair with autologous vein patch for cystic adventitial disease of the popliteal artery of a 57-year-old man presenting with pain, pallor, and paresthesia, without any postoperative complications or recurrence.
		                        		
		                        		
		                        		
		                        			Constriction, Pathologic
		                        			;
		                        		
		                        			Embolism
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Intermittent Claudication
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Pallor
		                        			;
		                        		
		                        			Paresthesia
		                        			;
		                        		
		                        			Popliteal Artery
		                        			;
		                        		
		                        			Postoperative Complications
		                        			;
		                        		
		                        			Recurrence
		                        			;
		                        		
		                        			Stents
		                        			;
		                        		
		                        			Vascular Diseases
		                        			;
		                        		
		                        			Veins
		                        			
		                        		
		                        	
9.A Case of Gastrointestinal Stromal Tumor with Recurrent Hypoglycemia.
Sun Hee KO ; Seok Hwan KIM ; Il Ho MAENG ; Koon Soon KIM ; Yi Sun JANG ; Hye Soo KIM ; Jong Min LEE ; Suk Young PARK ; Sang Bum KANG
Endocrinology and Metabolism 2010;25(2):125-130
		                        		
		                        			
		                        			Non-islet cell tumor induced hypoglycemia (NICTH) is attributable to overproduction of insulin-like growth factor-II (IGF-II) by solid tumors, and these tumors usually originate from mesenchymal or epithelial cells. Gastrointestinal stromal tumor (GIST) is a rare mesenchymal tumor and most commonly find in the gastrointestinal tract. It is usually expresses the CD117 (stem cell factor receptor, c-kit) detected by immunohistochemistry. Hypoglycemia associated with GIST is very rare and this has not yet been reported in Korea. A 72-year-old man was hospitalized due to frequent episodes of confusion. It was observed that non-hyperinsulinemic hypoglycemia, an elevated serum IGF-II level and a huge liver mass. The histology of liver mass showed c-kit (CD117) positivity, which was consistent with GIST, but it was surgically unresectable. He was treated with imatinib mesylate. Although he recieved palliative treatment, he still experienced intermittent fasting hypoglycemia. After 2 months, the serum IGF-II level was even higher than before. We changed imatinib mesylate to sunitinib malate and performed radiotherapy on the liver mass. Although the change of the liver mass was not significant, he did not suffer from hypoglycemia for three months afterwards.
		                        		
		                        		
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Benzamides
		                        			;
		                        		
		                        			Epithelial Cells
		                        			;
		                        		
		                        			Gastrointestinal Stromal Tumors
		                        			;
		                        		
		                        			Gastrointestinal Tract
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hypoglycemia
		                        			;
		                        		
		                        			Immunohistochemistry
		                        			;
		                        		
		                        			Indoles
		                        			;
		                        		
		                        			Insulin-Like Growth Factor II
		                        			;
		                        		
		                        			Korea
		                        			;
		                        		
		                        			Liver
		                        			;
		                        		
		                        			Mesylates
		                        			;
		                        		
		                        			Palliative Care
		                        			;
		                        		
		                        			Piperazines
		                        			;
		                        		
		                        			Pyrimidines
		                        			;
		                        		
		                        			Pyrroles
		                        			;
		                        		
		                        			Imatinib Mesylate
		                        			
		                        		
		                        	
10.Comparison between FDG Uptake and Clinicopathologic and Immunohistochemical Parameters in Pre-operative PET/CT Scan of Primary Gastric Carcinoma.
Eun Ji HAN ; Woo Hee CHOI ; Yong An CHUNG ; Ki Jun KIM ; Lee So MAENG ; Kyung Myung SOHN ; Hyun Suk JUNG ; Hyung Sun SOHN ; Soo Kyo CHUNG
Nuclear Medicine and Molecular Imaging 2009;43(1):26-34
		                        		
		                        			
		                        			PURPOSE: The purpose of this study was to find out what clinicopathologic or immunohistochemical parameter that may affect FDG uptake of primary tumor in PET/CT scan of the gastric carcinoma patient. MATERIALS AND METHODS: Eighty-nine patients with stomach cancer who underwent pre-operative FDG PET/CT scans were included. In cases with perceptible FDG uptake in primary tumor, the maximum standardized uptake value (SUVmax) was calculated. The clinicopathologic results such as depth of invasion (T stage), tumor size, lymph node metastasis, tumor differentiation and Lauren's classification and immunohistochemical markers such as Ki-67 index, expression of p53, EGFR, Cathepsin D, c-erb-B2 and COX-2 were reviewed. RESULTS: Nineteen out of 89 gastric carcinomas showed imperceptible FDG uptake on PET/CT images. In cases with perceptible FDG uptake in primary tumor, SUVmax was significantly higher in T2, T3 and T4 tumors than T1 tumors (5.8+/-3.1 vs. 3.7+/-2.1, p=0.002). SUVmax of large tumors (above or equal to 3 cm) was also significantly higher than SUVmax of small ones (less than 3 cm) (5.7+/-3.2 vs. 3.7+/-2.0, p=0.002). The intestinal types of gastric carcinomas according to Lauren showed higher FDG uptake compared to the non-intestinal types (5.4+/-2.8 vs. 3.7+/-1.3, p=0.003). SUVmax between p53 positive group and negative group was significantly different (6.0+/-2.8 vs. 4.4+/-3.0, p=0.035). No significant difference was found in presence of LN metastasis, tumor differentiation, Ki-67 index, and expression of EGFR, Cathepsin D, c-erb-B2 and COX-2. CONCLUSION: T stage of gastric carcinoma influenced the detectability of gastric cancer on FDG PET/CT scan. When gastric carcinoma was perceptible on PET/CT scan, T stage, size of primary tumor, Lauren's classification and p53 expression were related to degree of FDG uptake in primary tumor.
		                        		
		                        		
		                        		
		                        			Cathepsin D
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lymph Nodes
		                        			;
		                        		
		                        			Neoplasm Metastasis
		                        			;
		                        		
		                        			Stomach Neoplasms
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail